After the COVID-19 vaccine manufacturer Novavax (NVAX.O) raised concerns about its capacity to continue operating the day before, the company’s Frankfurt-listed shares dropped 26% on Wednesday.
The price of Novavax’s U.S.-listed stock dropped 25% on Tuesday after-hours trading.